Balasubramanyam Karanam to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Balasubramanyam Karanam has written about Dose-Response Relationship, Drug.
Connection Strength
0.171
-
Karthigeyan D, Siddhanta S, Kishore AH, Perumal SS, ?gren H, Sudevan S, Bhat AV, Balasubramanyam K, Subbegowda RK, Kundu TK, Narayana C. SERS and MD simulation studies of a kinase inhibitor demonstrate the emergence of a potential drug discovery tool. Proc Natl Acad Sci U S A. 2014 Jul 22; 111(29):10416-21.
Score: 0.100
-
Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, Kundu TK. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem. 2004 Dec 03; 279(49):51163-71.
Score: 0.051
-
Bazzaro M, Anchoori RK, Mudiam MK, Issaenko O, Kumar S, Karanam B, Lin Z, Isaksson Vogel R, Gavioli R, Destro F, Ferretti V, Roden RB, Khan SR. a,?-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells. J Med Chem. 2011 Jan 27; 54(2):449-56.
Score: 0.020